July 2021 - Page 3 of 5 - BioMedWire (BMW)

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

FridayJul 16, 2021 2:05 pm

Sleep Apnea, Genetic Predisposition Linked to Severe Coronavirus Infection

A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study, which was reported in the BMJ journals, noted that moderate to acute sleep apnea predisposes individuals to acute coronavirus. Other coronavirus risk factors include older age, diabetes and a high body mass index. The researchers used FinnGen data for their study, which was backed by the Center of Excellence in Complex Disease Genetics. The researchers linked data obtained from the Finland National Infectious Disease Register on coronavirus…

FridayJul 16, 2021 1:58 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

FridayJul 16, 2021 9:30 am

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection. A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting. As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space. As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered…

ThursdayJul 15, 2021 1:08 pm

Report Finds That Use of Remote Health Has Grown Significantly

A recent survey conducted in the second quarter of this year by Parks Associates has found that more than one-half of broadband households own an internet-enabled fitness or health device that records biometric data, with another two-thirds revealing that they have undergone remote health consultation. The survey, which involved 5,000 broadband households in the United States was conducted by Parks Associates, a market research and consulting firm that specializes in emerging consumer technology products. Parks Associates senior analyst Kristen Hanich stated that the overall familiarity with telehealth had assisted in driving the connected health device market. Hanich noted that there…

WednesdayJul 14, 2021 11:43 am

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developer Piezo Motion's technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatments Merger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced that it has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric…

WednesdayJul 14, 2021 10:00 am

Researchers May Have Found Way to Retain Bladder After Bladder Cancer Diagnosis

Cancer metastasis is every patient and doctor’s nightmare when it comes to treating this deadly disease. Chemotherapy is usually the primary treatment option, with doctors following up with surgeries to remove any tumors. However, patients suffering from muscle-invasive bladder cancer have to make a life-altering decision to either undergo chemotherapy and have their bladder removed to reduce chances of the cancer recurring or take their chances with the cancer metastasizing and leave their bladder intact while undergoing chemotherapy. Cystectomy, which refers to the surgical removal of the bladder, is the standard treatment plan for individuals who suffer from muscle-invasive bladder…

TuesdayJul 13, 2021 10:13 am

Study Explores Debilitating Childhood Brain Cancer Treatment Options

A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at the Washington University in St. Louis proposes that young patients with an average risk medulloblastoma can, after a six-week radiation treatment regimen, undergo a radiation boost to a smaller area of the brain. Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard of care for this type of cancer includes radiation therapy to the whole spine and brain, after which an extra dose of radiation to the back of the…

MondayJul 12, 2021 12:50 pm

Cognitive Problems in Childhood Could Trigger Mental Health Issues Later in Life

New research conducted by a group of scientists from Finland and the UK, led by a team from University of Birmingham, has found that children who experience cognitive difficulties such as a lack of inhibition, poor memory or low attention may suffer from mental health problems as young adults or teenagers. On a global scale, mental disorders affect about 10% of adolescents and children, with researchers finding that 75% of the disorders diagnosed in adulthood usually begin during adolescence or childhood. For instance, disorders such as psychosis, depression and bipolar disorder often emerge during adolescence and continue into adulthood. The…

MondayJul 12, 2021 12:42 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: July 2021

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

Sleep Apnea, Genetic Predisposition Linked to Severe Coronavirus Infection

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

Report Finds That Use of Remote Health Has Grown Significantly

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

Researchers May Have Found Way to Retain Bladder After Bladder Cancer Diagnosis

Study Explores Debilitating Childhood Brain Cancer Treatment Options

Cognitive Problems in Childhood Could Trigger Mental Health Issues Later in Life

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search